Takeda presented new real-world data highlighting the underdiagnosis of hemophilia A and B, supporting the effectiveness and safety of its…
Articles by Ana Pena, PhD
Catalyst Biosciences has announced new clinical data supporting the safety and efficacy of its lead candidate therapies…
Joint changes detected by magnetic resonance imaging (MRI), and often are missed on radiographs, are a strong predictor of…
Aptevo Therapeutics announced the dosing of a first patient in a Phase 4 study aiming to extend use of…
The likelihood that teenagers and young adults with hemophilia will use a prophylactic replacement therapy as prescribed is mostly influenced by…
Adults and children with severe hemophilia A who are receiving Nuwiq (recombinant human coagulation factor VIII) as their…
Takeda has presented new real-world data to support the cost-effectiveness and persistent benefits to patients of its hemophilia…
Takeda has presented early data on the prevalence of — and a possible solution for — one of gene therapy’s…
New preclinical data on one of Catalyst Biosciences’ lead candidate therapies — marzeptacog alfa activated (MarzAA), an engineered clotting Factor VIIa…
Enzyre is teaming up with Takeda to develop a diagnostic device that will allow people with hemophilia…